504 related articles for article (PubMed ID: 35875026)
41. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
42. An immunogenic cell death-related classification predicts response to immunotherapy and prognosis in triple-negative breast cancer.
Cheng XY; Liang Y; Zhang HF; Qian FZ; Sun XH; Liu XA
Am J Transl Res; 2023; 15(4):2598-2609. PubMed ID: 37193173
[TBL] [Abstract][Full Text] [Related]
43. Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer.
Luo H; Hong R; Xu Y; Zheng Q; Xia W; Lu Q; Jiang K; Xu F; Chen M; Shi D; Deng W; Wang S
Gland Surg; 2023 Feb; 12(2):225-242. PubMed ID: 36915811
[TBL] [Abstract][Full Text] [Related]
44. Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits.
Chang Q; Fan L; Li M; Liu L
Medicine (Baltimore); 2023 Feb; 102(8):e33059. PubMed ID: 36827041
[TBL] [Abstract][Full Text] [Related]
45. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
[TBL] [Abstract][Full Text] [Related]
46. Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer.
Xia H; Xu X; Guo Y; Deng X; Wang Y; Fu S
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38136994
[TBL] [Abstract][Full Text] [Related]
47. Identification of new subtypes and potential genetic signatures in triple-negative breast cancer using weighted gene co-expression network analysis.
Huang J; Liao LY; Jiang WJ; Li YH; Lu BM; Wen ZP; Li FJ; Fang DL; Lu GM
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):603-614. PubMed ID: 38305604
[TBL] [Abstract][Full Text] [Related]
48. Identification of molecular subtypes and a six-gene risk model related to cuproptosis for triple negative breast cancer.
Zhu B; Wang S; Wang R; Wang X
Front Genet; 2022; 13():1022236. PubMed ID: 36386788
[No Abstract] [Full Text] [Related]
49. Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer.
Hu S; Qu X; Jiao Y; Hu J; Wang B
Front Genet; 2021; 12():710534. PubMed ID: 34795691
[No Abstract] [Full Text] [Related]
50.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
51. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
53. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
54. Bioinformatics Analysis Identifies IL6ST as a Potential Tumor Suppressor Gene for Triple-Negative Breast Cancer.
Jia R; Weng Y; Li Z; Liang W; Ji Y; Liang Y; Ning P
Reprod Sci; 2021 Aug; 28(8):2331-2341. PubMed ID: 33650093
[TBL] [Abstract][Full Text] [Related]
55. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
56. Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC.
Wu H; Feng J; Zhong W; Zouxu X; Xiong Z; Huang W; Zhang C; Wang X; Yi J
Front Immunol; 2023; 14():1151800. PubMed ID: 36999020
[TBL] [Abstract][Full Text] [Related]
57. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
58. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
59. Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235.
Feng J; Wang L; Zhang K; Ni S; Li B; Liu J; Wang D
Sci Rep; 2023 Apr; 13(1):5984. PubMed ID: 37045929
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
